Kinross Class Action Lawsuit Allegations
The Kinross class action lawsuit asserts securities fraud claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 on behalf of investors in Kinross stock. The class action is pending in the U.S. District Court for the District of Colorado. It is captioned Lin v. Kinross Gold Corporation, No. 26-cv-5910.
If you lost money on your Kinross investment, you are encouraged to submit your information using the form on this page. You may also email adam@bfalaw.com or call 212.789.3619.
Why is Kinross Being Sued for Securities Fraud?
Kinross has been sued for securities fraud following a significant stock drop resulting from alleged violations of the federal securities laws. The decline in Kinross’ stock price caused significant losses to investors.
Kinross is a Canadian gold mining company with regional offices and mining facilities in the United States and abroad. Notably, Kinross operates Round Mountain, an open-pit gold mine in Nye County, Nevada.
According to the complaint, Kinross projected 2026 attributable production of 2.0 million gold equivalent ounces and repeatedly assured investors that it was “[o]n track to meet annual guidance” and “remain[ed] solidly on track to produce 2 million ounces.”
As alleged, Defendants failed to disclose that Kinross did not have the necessary resources and was otherwise ill-equipped to achieve its projections.
Why did Kinross’ Stock Drop?
On September 23, 2026, Kinross issued an “Operational and Return of Capital Update” mid-quarter. In the release, Kinross cut full year 2026 and 2027 attributable production guidance to 1.84 million to 1.86 million gold equivalent ounces. Kinross attributed the cut, in significant part, to ore recovery challenges at Round Mountain. The company later disclosed these challenges were operational in nature and were likely due to the use of oversized tools and machinery in the mining process.
On this news, Kinross stock dropped $3.20 per share, or 11.5%, from a closing price of $27.62 per share on September 23, 2026, to $24.42 per share on September 24, 2026.
Kinross ($KGC) Stock Chart
Image Caption: NYSE online chart showing the Kinross (KGC) stock drop following the September 2026 disclosure.
What is the Kinross Lead Plaintiff Deadline?
You may ask the Court no later than January 5, 2027, to appoint you as Lead Plaintiff through counsel of your choice.
To be a member of the Class, you need not take any action at this time. The ability to share in any potential future recovery is not dependent on serving as Lead Plaintiff.
How Do I Submit My Information?
If you lost money when Kinross securities dropped in price, you are encouraged to submit your information using the form on this page to speak with an attorney about your rights.
You can also contact:
Adam McCall
amccall@bfalaw.com
212.789.3619
All representation is on a contingency fee basis; there is no cost to you. Shareholders are not responsible for any court costs or expenses of any class action lawsuit. The firm will seek court approval for any potential fees and expenses.
Why Bleichmar Fonti & Auld LLP?
BFA is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It has been named a top plaintiff law firm by Chambers USA, The Legal 500, and ISS SCAS.
BFA attorneys have been named “Elite Trial Lawyers” by the National Law Journal, “Litigation Stars” by Benchmark Litigation, among the top “500 Leading Plaintiff Financial Lawyers” by Lawdragon, “Titans of the Plaintiffs’ Bar” by Law360, and “Super Lawyers” by Thomson Reuters.
Most recently, The Legal 500 awarded BFA the most client satisfaction accolades of any plaintiff’s securities litigation law firm, with clients noting: “[t]here is no better service provider in the practice area,” “[t]he interest of the client is always front and center,” and “[t]here isn’t a better firm in this space.” One testimonial described the firm as “nimble and entrepreneurial,” with a “relentless focus on adding value for clients.”
BFA’s notable successes include a recovery of over $900 million in value from Tesla, Inc.’s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Attorney advertising. Past results do not guarantee future outcomes.
